pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-708 |
Genomic Coordinates | chr11: 79402022 - 79402109 |
Synonyms | MIRN708, hsa-mir-708, MIR708 |
Description | Homo sapiens miR-708 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-708-5p | ||||||||||||||||||||||||||||
Sequence | 11| AAGGAGCUUACAAUCUAGCUGGG |33 | ||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ZEB2 | ||||||||||||||||||||
Synonyms | HSPC082, SIP-1, SIP1, SMADIP1, ZFHX1B | ||||||||||||||||||||
Description | zinc finger E-box binding homeobox 2 | ||||||||||||||||||||
Transcript | NM_001171653 | ||||||||||||||||||||
Other Transcripts | NM_014795 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ZEB2 | |||||||||||||||||||||
3'UTR of ZEB2 (miRNA target sites are highlighted) |
>ZEB2|NM_001171653|3'UTR
1 TAAACTACTGCATTTTAAGCTTCCTATTTTTTTTTCCAGTAGTATTGTTACCTGCTTGAAAACACTGCTGTGTTAAGCTG
81 TTCATGCACGTGCCTGACGCTTCCAGGAAGCTGTAGAGAGGGACAGAAGGGGCGGTTCAGCCAAGACAGATGTAGACGGA
161 GTTGGAGCTGGGTATTGTTAAAAACTGCATTATGCAAAAATTTTGTACAGTGTTAAGGCCTAAAAACTGTGTGGTTCAGA
241 GACTAATTCCTGTGTTTAATAGCATTTATACTTTAAGCACAACTAGAAAATTGTAAGAATTGCACTCTACTTATGTATCA
321 CTACAAACTTTAAAAAACTATGTCTAATTTATATTAATACATTTTAAAAAGGTGCCCGCACTACCATACATCAGTATTTT
401 TATTATTATTATTGTTATTCCTTTTTAATTTAATGTGCTCGCACTACAATGCATCAGTATTATGATTCCTCTGTACTTTC
481 CTTTCGCTATTCATCAATTTCCCATTTTTTTTTTCAGCTTAAGTAACCACACAATTTTAGGCCTCAATTTTTTTTTTTTT
561 CTGTGAAGGAACTTGAAGTGATGCATGTGTGAATTTAAGATACCGAAGTCTTAAAGTGACCTGGACGTGAAGGAAAAAGT
641 AAGATGAGAAATAAAGAAAGCCTTTGTAAGGTGGTTTTAAAAGCCTTATATGCAAACCTTTTAATCTGTGTTTCTGCAAG
721 TGCCATCCTTGTACAGTGTTAAGAGGGTAACATGGGTTACCTTTGCACCAGCTTCAGTGTTAAGCTCACCCTGTTCTTTG
801 AAGCACCCATGTCAGTATTAGAAGAATAGGCAGCAGTTCCTTAGTTTACATATGTTTGTGCAATTATTTTCTGTACTTTT
881 TTGTTCATTAATTTTGTCAGTATTACACCAAACTGTTTTTGCAACAAAAAAATTTTTTTTGCATTCATTTAATTTTAGGT
961 CAAATAACATTTTATTTATGTGGCTCATTTTATATTTCCTAATTTTATTTATTTCATACTGTAGTGTACAGTATTATAGT
1041 TCTTCAATATATAGATATATTTTAGTAAAAAAGGAACATGACGTTGATCATTTGGGCAAATTTTACGTAAAGAGAAGAGC
1121 ATTTATTGTGTTTTGGAACATTAATTGTGAGATGGGATTTTTCAATTTTATTATTTTATTTTTGTTTTTTTCCAATTACT
1201 GGAAATTCCAAATTTGGGAACTTTTGATACGATCTTGTGAAAACACTGTATTTTCGACTGAAAATTCCACTTTCTTCATC
1281 TTGTTTTTTAGCTAAAAAGAGGGACTGTTAAATACAATGTATGATACCATGACAAAAATCTTTCCTGAATTGTCTTTGTA
1361 AAAGTATTATTGAATTTTCAATTTGTAATTTCTTTTGAAAATGACCATGCTCGAATAAAAATGTAGCCAAACTAAGAATG
1441 TAGTTAATGAGTTCTGTACTTTTAGAGAGTTTTCCTTCAATGACCATTAACATGTAACATGCTTTATGCTTATAATAATG
1521 CTAATTATGTTTTTTTCATATAATTTTAGTTTAGCAATAATTTTGACTGGTACCAATAACTGTTTTTTAAAATTCCATAC
1601 CTATGTACAGCAATTTTACAGCTTTTCTCAACTGATCCTGATTCCAGATTGTGTATTTTTATGTGAGGTTATATTATTCA
1681 AATTTAGTCTATTTACTTTACAGACATTTCTACTTTTGCATTACGAGTATTTAGAGATTATGTGTTAAAAATTCACTTCT
1761 CTGTCCAAGGGGTCTTTGTGATTTATTCAAAAAAAAGTCTAATTTCAAAAAGACAGCTATTATTCAGTGTTATTTATAAT
1841 ATGTAACCTTTTTTAAAGGATTGGGATAGTTTATCTCACTTTTTGAAATGCAGACAGTAGTTTACCGTTTATCTGAAACT
1921 AGAAGGCGTGGGTGGGAGAGGAAAAGCTAAAAGCAAATGCTAACAAAAATAACCGTGATTTTCTAAGACAGTTTTTCAGT
2001 TTTTACAAGATGACCCTAATATTCAGAATATGAATGTATTCGTAGGTTTTACATAATGACTTTTATCAAGAAACTAGATT
2081 CTGCTTCTTAAATCTAATTGCCAAGTGAAGAATAACAGAAAAAACAGATTACCTTATCAAATTTACAGCTCTTGAATATA
2161 CAGAACTATAATATAGTAGCTGTCCATGTATTTTTTCTACTTTAGAATCAAAGAAGAAAAGCATCATTTTGCTATTAAAT
2241 TTGCTAAAATTTTGAGTATGATATTTCCAGTTGGCAAGAACAACATATTTATATTTATTCCTTAGCCATAATACCACTTT
2321 CCTAAATTTCACAAAAGTCATTCTTTGCAACTTGAAACTCAATAGAAAGTGTGTATGTGTGTGTGTGTATATATATATAT
2401 ATATACACACACACACATACACAGAAAGGATGTAATGAAGATACAGTAATAGTTGAGCAGACCTTTTTAGAAAAACATGT
2481 TTTTAGCTCTATCTTCAAACTTTCTGGCAGAGGGGGTGGGGGGGGCAGGGGGAGGAGTGGCATCAAAATGCTATGCCTCC
2561 TGTTATCCACAGCCTAGAGTTTTTATATTTGGAAAGTTTAGAAAATTCTATCCTCGTTTCTCCTTCTTTGAATGGCACAA
2641 ATAAATACACTACATAAATTTTTCTGGTTTGAAAGGCTCTAGGCGATAACTTTATTAATTCAACCTGAAAATATCAAGCC
2721 ATTAAATTTTGTCCGGGTAGAATAAATCCCTGTGGCCTCTTTTAAAGCAATGTAGGTCTCTGTTGCCCATGGGGCATATC
2801 TGTGTCCCAATCCACAAGAGATAGGACCAACAAACAATGAATGTGCAACCTAACTCTTTCTCCTTGGAAAGAAGAAAGTG
2881 TGCACGAAGTAGAGGAGGGTGGGCAGACCCTGCCTTGCCCCTCCTGTTACCCCCTTCTCTGTCATTTGTTCCTAACTCCA
2961 TTTCATAGGCAGGCTCAGAATACCTGAGTCTGAAAATATCAGGATAACACTTGTGAATTGTGACAATCACTACAATGTCC
3041 CATATCTGAGGAGTTTTTTTTAATGCTATTTATCCGCTGGACACGATTGCACATTAGGGCTGCATAATCCTCTAACTCTA
3121 GGGAAAAATAAAAACTTTTGATTTGTCTTAAGATTCTTCTCCAAGGTCGCAAACAAGAAATTCCCCTCCACAACCAAGAG
3201 ATGTGCATTTTAGTAACATCAGATGTGTTCTTCTGTTTTATCAACTACTTACTCTTCCCACACGCTTAGTTCTAAATCTA
3281 ACCTTTCCCCCCTCGAATAGGGGGCAGGGGAGGATGAGGAAACACTGGAACAACTGAACACCCCTGCCCATTTTCTCCAA
3361 GAGCCTTTTGTATTCTAGCATATCTGTGCAATCTTTTCTTTTTTCTTCACATGACACTGTAAGCTTAGGCCTGAAATAAC
3441 TGGGAAGAGAGATGCGTATCAGAATTTCTCCGCAAGAGCTAAACAAAACATACATCTTCCTTAGCATGAATTGGACTGGG
3521 GGCGGAGTGGGAGGGCTTGGAGGAAAGGGGAAAGAAGGGACTATATTTGAATAAATATGAATAAATGTATTAGATACTTT
3601 TCACAATCAGATAACTTTTAAAAAGGTCATTTTTTATCTTTCTAATAATGTAAGCCTTAATAAAAGCAAATCTTAGTCAC
3681 AAATTTGAGGAGACTGCCCAATAATAAGTTTACATGTATTTGAACTGAAAAATTGTTAACCATGCTTTTGCTCCAAGATG
3761 TGTGAGGCCATTCAGGGGCTGTAGGGCCCTGGATATACACACAAACAAGTGTGTGTATATCTGGAGCCCCACACATTGTA
3841 ATAAACACAGCTGCATTTATTTGACTATGTGATCCCATGTACATGTAAAAACATTCAAACAAACACACTCAGCGGATTTA
3921 TTTATTGTGCAATGGGGCAATTATTCAAATAAACATGCTCAATGCAATTATTTGAATCTCACATTGCATGTTCATCAATC
4001 ATAGCACTAAAAAAAGAGGGGGAAAAAACACCAAAGAATTCACATGGGGAAAAAATATATATATGAAAACCACCTTATTA
4081 TAGATTTTATAGGGCAGCTGAGGTTATGGCTCCCTTCTTAACTGTAACTCAACTATTCTGTATTCAATGACATTTGTTTC
4161 TAATGATTAATTGGTTCACTCACTTGATCATATAATAGCAAACTTTATAAACCTGTATTGTGTAGAGATGTGAAATCTCT
4241 ATATTTCAAGAGCAGAAGAGTTCTTTCTAGACACCTTACATCAAGGGACACTGGTCCAATTATTATCGCTTATATAAGCA
4321 CTCCTATAAATTCTGAAAAATTTTATACATGCAACAAAACATTCCTACATTTGAAGACATTAAGAAAAATCACAGGTGAC
4401 TCATCTGATCATTCTATATATTAATAAATATTATGACATATATGTGAACACATCACAAATCATATTGGTGTACCAAGAGG
4481 CAATTTATGCCTCTCTTAAGTATGTACTGACATAACCTAATATACTAAAATGGGAAGGGGCTTTTAGTCACTGAAATATG
4561 CATCGTGTAACAAAGATGAAGAAAATACATGGCTTGTGCCCATCATAAAAAAAGATTCAGACTGAAGGCTTAGCTTTGGT
4641 TTTTTCAATTAAATTGTTAAACTGTGCACAGTGATTTTTTTTTAGAACTTGAGACATTTGTGATGTTGGCTGTTTAAATC
4721 TTTGTTACCTTCGCTGTGAATTGAAATTGTACATATTTAGTAAATCATGCAGACAAAACAAACTTTTTAGACAATATTTT
4801 TATTGGAGAGTTTTCTTTTCCTGTATCCATGTTAAAAAAAAAAAAGACCTCCTTTCCCAAAATAAAAATGTCAATACTAA
4881 ATTTAAAGAAGTATAAAGGAATGATTGCTTCCTTTAGAGCAAAATATTTAAATAAACATGGAGATAATTGGCAACATGTT
4961 CTTTTTGGGCTAGTAGGCTGTGTCCAATTTTTTGGGTCTGATGTTTCAGAGGGCCTCTGTTTCAGGGTTGAAGATGATAT
5041 ATTAATCTCGGAATTAAACAAATGCTATTAAATAAC
Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HK2 , A-498 , Caki-2 |
Disease | Renal cell carcinoma |
Location of target site | 3'UTR |
Tools used in this research | miRanda |
Original Description (Extracted from the article) |
...
3'UTR of ZEB2 and BMI1 are functional targets of miR-708 in renal cancer
... - Saini S; Yamamura S; Majid S; Shahryari V; et al., 2011, Cancer research. |
Article |
- Saini S; Yamamura S; Majid S; Shahryari V; et al. - Cancer research, 2011
Cancer pathogenesis is restricted by stresses that compromise cell division and survival. In this study, we identify miR-708, a little studied member of a set of microRNAs that have been implicated in stress control, as an important tumor suppressor in renal cell carcinoma (RCC). miR-708 expression was attenuated widely in human RCC specimens. Restoration of miR-708 expression in RCC cell lines decreased cell growth, clonability, invasion, and migration and elicited a dramatic increase in apoptosis. Moreover, intratumoral delivery of miR-708 was sufficient to trigger in vivo regression of established tumors in murine xenograft models of human RCC. Investigation of the targets of miR-708 identified the inhibitor of apoptosis protein survivin as important. siRNA-mediated knockdown of survivin partially phenocopied miR-708 overexpression suggesting that the proapoptotic role of miR-708 may be mediated primarily through survivin regulation. Additionally, we identified the E-cadherin regulators ZEB2 and BMI1 as likely miR-708 targets. Taken together, our findings define a major tumor suppressive role for miR-708, which may offer an attractive new target for prognostic and therapeutic intervention in RCC.
LinkOut: [PMID: 21852381]
|
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
82 hsa-miR-708-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT006139 | BMI1 | BMI1 proto-oncogene, polycomb ring finger | 4 | 1 | ||||||||
MIRT006140 | ZEB2 | zinc finger E-box binding homeobox 2 | 4 | 1 | ||||||||
MIRT006141 | BIRC5 | baculoviral IAP repeat containing 5 | 4 | 1 | ||||||||
MIRT006473 | AKT2 | AKT serine/threonine kinase 2 | 2 | 1 | ||||||||
MIRT006474 | CD44 | CD44 molecule (Indian blood group) | 2 | 1 | ||||||||
MIRT006941 | TMEM88 | transmembrane protein 88 | 2 | 1 | ||||||||
MIRT037743 | RANBP2 | RAN binding protein 2 | 1 | 1 | ||||||||
MIRT037744 | RNF41 | ring finger protein 41 | 1 | 1 | ||||||||
MIRT037745 | SMG5 | SMG5, nonsense mediated mRNA decay factor | 1 | 1 | ||||||||
MIRT037746 | FAM92A1 | family with sequence similarity 92 member A | 1 | 1 | ||||||||
MIRT037747 | COX1 | cytochrome c oxidase subunit I | 1 | 1 | ||||||||
MIRT037748 | KMT2C | lysine methyltransferase 2C | 1 | 1 | ||||||||
MIRT037749 | YKT6 | YKT6 v-SNARE homolog | 1 | 1 | ||||||||
MIRT037750 | C14orf93 | chromosome 14 open reading frame 93 | 1 | 1 | ||||||||
MIRT037751 | VPS29 | VPS29, retromer complex component | 1 | 1 | ||||||||
MIRT037752 | TUBB | tubulin beta class I | 1 | 1 | ||||||||
MIRT037753 | NRCAM | neuronal cell adhesion molecule | 1 | 1 | ||||||||
MIRT037754 | MARCKSL1 | MARCKS like 1 | 1 | 1 | ||||||||
MIRT037755 | SEC14L1 | SEC14 like lipid binding 1 | 1 | 1 | ||||||||
MIRT037756 | TOP2A | DNA topoisomerase II alpha | 1 | 1 | ||||||||
MIRT037757 | CPSF3 | cleavage and polyadenylation specific factor 3 | 1 | 1 | ||||||||
MIRT037758 | SMAP2 | small ArfGAP2 | 1 | 1 | ||||||||
MIRT053062 | EYA3 | EYA transcriptional coactivator and phosphatase 3 | 3 | 1 | ||||||||
MIRT054899 | NNAT | neuronatin | 1 | 1 | ||||||||
MIRT255134 | SMYD1 | SET and MYND domain containing 1 | 2 | 4 | ||||||||
MIRT317837 | CCND3 | cyclin D3 | 2 | 2 | ||||||||
MIRT367648 | ARHGAP42 | Rho GTPase activating protein 42 | 2 | 4 | ||||||||
MIRT437386 | AKT1 | AKT serine/threonine kinase 1 | 2 | 1 | ||||||||
MIRT437387 | CCND1 | cyclin D1 | 2 | 1 | ||||||||
MIRT437388 | MMP2 | matrix metallopeptidase 2 | 2 | 1 | ||||||||
MIRT437389 | EZH2 | enhancer of zeste 2 polycomb repressive complex 2 subunit | 2 | 1 | ||||||||
MIRT437390 | PARP1 | poly(ADP-ribose) polymerase 1 | 2 | 1 | ||||||||
MIRT437391 | BCL2 | BCL2, apoptosis regulator | 2 | 1 | ||||||||
MIRT437789 | CASP2 | caspase 2 | 3 | 1 | ||||||||
MIRT438400 | CD274 | CD274 molecule | 2 | 1 | ||||||||
MIRT438715 | CNTFR | ciliary neurotrophic factor receptor | 3 | 1 | ||||||||
MIRT443875 | DDTL | D-dopachrome tautomerase like | 2 | 2 | ||||||||
MIRT447542 | RNF165 | ring finger protein 165 | 2 | 2 | ||||||||
MIRT447609 | PCYOX1 | prenylcysteine oxidase 1 | 2 | 2 | ||||||||
MIRT447836 | CTIF | cap binding complex dependent translation initiation factor | 2 | 2 | ||||||||
MIRT448192 | FAM168A | family with sequence similarity 168 member A | 2 | 2 | ||||||||
MIRT448711 | KLHL11 | kelch like family member 11 | 2 | 2 | ||||||||
MIRT450177 | KLF7 | Kruppel like factor 7 | 2 | 2 | ||||||||
MIRT450310 | DRAXIN | dorsal inhibitory axon guidance protein | 2 | 2 | ||||||||
MIRT460790 | VPS37B | VPS37B, ESCRT-I subunit | 2 | 2 | ||||||||
MIRT466329 | THRA | thyroid hormone receptor, alpha | 2 | 2 | ||||||||
MIRT467608 | SLC7A5 | solute carrier family 7 member 5 | 2 | 2 | ||||||||
MIRT471607 | PAQR5 | progestin and adipoQ receptor family member 5 | 2 | 2 | ||||||||
MIRT472142 | NKIRAS2 | NFKB inhibitor interacting Ras like 2 | 2 | 4 | ||||||||
MIRT476589 | G3BP1 | G3BP stress granule assembly factor 1 | 2 | 4 | ||||||||
MIRT486263 | LINC00346 | long intergenic non-protein coding RNA 346 | 2 | 4 | ||||||||
MIRT486478 | TSC22D1 | TSC22 domain family member 1 | 2 | 2 | ||||||||
MIRT487976 | IQSEC2 | IQ motif and Sec7 domain 2 | 2 | 2 | ||||||||
MIRT489426 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT500779 | TMED4 | transmembrane p24 trafficking protein 4 | 2 | 6 | ||||||||
MIRT501233 | SEMA4C | semaphorin 4C | 2 | 6 | ||||||||
MIRT511043 | NRF1 | nuclear respiratory factor 1 | 2 | 2 | ||||||||
MIRT512835 | IER3 | immediate early response 3 | 2 | 2 | ||||||||
MIRT513089 | USP9X | ubiquitin specific peptidase 9, X-linked | 2 | 2 | ||||||||
MIRT513541 | PRDM2 | PR/SET domain 2 | 2 | 4 | ||||||||
MIRT532389 | UMPS | uridine monophosphate synthetase | 2 | 2 | ||||||||
MIRT535844 | MSI2 | musashi RNA binding protein 2 | 2 | 2 | ||||||||
MIRT537890 | EDA2R | ectodysplasin A2 receptor | 2 | 2 | ||||||||
MIRT552768 | YIPF6 | Yip1 domain family member 6 | 2 | 2 | ||||||||
MIRT553547 | TMEM167A | transmembrane protein 167A | 2 | 4 | ||||||||
MIRT557227 | HNRNPC | heterogeneous nuclear ribonucleoprotein C (C1/C2) | 2 | 2 | ||||||||
MIRT566754 | MORF4L1 | mortality factor 4 like 1 | 2 | 2 | ||||||||
MIRT567503 | FOXJ3 | forkhead box J3 | 2 | 2 | ||||||||
MIRT568163 | CCDC6 | coiled-coil domain containing 6 | 2 | 2 | ||||||||
MIRT570261 | PRSS16 | protease, serine 16 | 2 | 2 | ||||||||
MIRT614728 | TEAD3 | TEA domain transcription factor 3 | 2 | 2 | ||||||||
MIRT668892 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 | 2 | 2 | ||||||||
MIRT691019 | CRTC3 | CREB regulated transcription coactivator 3 | 2 | 2 | ||||||||
MIRT697419 | ZFP91 | ZFP91 zinc finger protein | 2 | 2 | ||||||||
MIRT711472 | SRD5A1 | steroid 5 alpha-reductase 1 | 2 | 2 | ||||||||
MIRT720188 | CMC4 | C-X9-C motif containing 4 | 2 | 2 | ||||||||
MIRT720620 | PIANP | PILR alpha associated neural protein | 2 | 2 | ||||||||
MIRT731442 | SMAD3 | SMAD family member 3 | 1 | 1 | ||||||||
MIRT736023 | TNF | tumor necrosis factor | 2 | 0 | ||||||||
MIRT736512 | DSPP | dentin sialophosphoprotein | 3 | 0 | ||||||||
MIRT736513 | DMP1 | dentin matrix acidic phosphoprotein 1 | 3 | 0 | ||||||||
MIRT756044 | SSRP1 | structure specific recognition protein 1 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|